Related Experiment Video

Updated: Jul 2, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Effect of picroliv administration on hepatic microsomal mixed function oxidases and glutathione-conjugating enzyme

J N Dhuley1

  • 1Pharmacology & Toxicology section, Research Centre, Hindustan Antibiotics Limited, Pimpri, Pune 411 018, India. dr_jaynil@yahoo.com

Hindustan Antibiotics Bulletin
|August 14, 2008
PubMed

Insights

Picroliv, a herbal compound, effectively combats cholestatic liver injury in rats by preventing biochemical damage. This suggests Picroliv possesses significant anti-cholestatic properties, potentially through antioxidant mechanisms.

Area of Science:

  • Hepatology
  • Pharmacology
  • Biochemistry

Background:

  • Cholestatic liver injury, induced by bile duct ligation in rats, significantly elevates serum markers and hepatic hydroxyproline.
  • This injury impairs hepatic microsomal mixed-function oxidases (MFO) and suppresses glutathione S-transferase activity.
  • Hepatic glutathione levels remain unaffected during cholestasis.

Purpose of the Study:

  • To investigate the effect of Picroliv on MFO and glutathione conjugating enzyme systems in cholestatic rats.
  • To evaluate the potential anti-cholestatic activity of Picroliv.

Main Methods:

  • Bile duct ligation was performed in male rats to induce cholestasis.
  • Serum and liver biochemical parameters were analyzed.
  • Rats were orally administered Picroliv (25 mg/kg/day for 21 days).

Main Results:

  • Picroliv administration significantly prevented the rise in serum sorbitol dehydrogenase and bile acid concentrations.
  • Picroliv mitigated the decrease in cytochrome P-450 content and the activities of NADPH-cytochrome C reductase and aminopyrine demethylase.
  • The suppression of hepatic glutathione S-transferase activity was significantly prevented by Picroliv.

Conclusions:

  • Picroliv demonstrates significant anti-cholestatic activity in a rat model of bile duct ligation.
  • The protective effects of Picroliv may be linked to its antioxidant properties or a role in protein synthesis.

More Related Videos

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride (CCl4) Exposure Through an Orogastric Tube

Published on: April 28, 2020

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model09:22

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model

Published on: April 2, 2017

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...